Literature DB >> 1556699

The incidence and prognosis of central nervous system disease in systemic lupus erythematosus.

J T Sibley1, W P Olszynski, W E Decoteau, M B Sundaram.   

Abstract

In a review of our experience with systemic lupus erythematosus (SLE) since 1975, we found 48 of 266 patients with major central nervous system (CNS) manifestations for which a non-SLE explanation could not be identified. Eleven patients developed more than one type of CNS event. The commonest symptom was seizure (18 patients), followed by brainstem dysfunction (12 patients), psychosis (11 patients), organic brain syndrome (11 patients) and stroke (7 patients). In 19% of cases, CNS manifestations were accompanied by a flare of multisystem SLE disease activity. Anticonvulsants were able to be discontinued safely in the majority of patients with seizures. Most CNS events were self-limited, reversible and not associated with poor outcome unless accompanied by multisystem disease activity. Therapy with corticosteroids did not appear to offer substantial benefit.

Entities:  

Mesh:

Year:  1992        PMID: 1556699

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  35 in total

Review 1.  Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature.

Authors:  K Warnatz; H H Peter; M Schumacher; L Wiese; A Prasse; F Petschner; P Vaith; B Volk; S M Weiner
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

Review 2.  Neuropsychiatric lupus.

Authors:  J G Hanly
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

3.  Reduced Insular Glutamine and N-acetylaspartate in systemic lupus erythematosus: a single-voxel (1)H-MR spectroscopy study.

Authors:  Patricia Cagnoli; Richard E Harris; Dan Frechtling; George Berkis; Richard H Gracley; Courtney C Graft; Suzan E Lowe; Thomas L Chenevert; William J McCune; Stephen Gebarski; Pia C Sundgren
Journal:  Acad Radiol       Date:  2013-10       Impact factor: 3.173

4.  Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus.

Authors:  Laura J Julian; Chris Tonner; Ed Yelin; Jinoos Yazdany; Laura Trupin; Lindsey A Criswell; Patricia P Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

5.  Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case-control study from a single center.

Authors:  Melissa Padovan; Gabriella Castellino; Alessandra Bortoluzzi; Luisa Caniatti; Francesco Trotta; Marcello Govoni
Journal:  Rheumatol Int       Date:  2010-07-31       Impact factor: 2.631

6.  Brainstem Reflexes in Systemic Lupus Erythematosus Patients Without Clinical Neurological Manifestations.

Authors:  Celal Salcini; Birgül Baştan; Gülin Sunter; Pınar Kahraman Koytak; Orhan Yilmaz; Tülin Tanridağ; Önder Us; Kayıhan Uluç
Journal:  Noro Psikiyatr Ars       Date:  2017-01-02       Impact factor: 1.339

7.  Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment.

Authors:  V Harisdangkul; D Doorenbos; S H Subramony
Journal:  J Neurol       Date:  1995-05       Impact factor: 4.849

Review 8.  Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.

Authors:  Virginia Fernandes Moça Trevisani; Aldemar A Castro; João Ferreira Neves Neto; Alvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

9.  Neuropsychiatric manifestations of systemic lupus erythematosus: Iranian experience.

Authors:  Afshin Borhani Haghighi; Shahab Ghasem Haza
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

10.  Secondary psychoses: an update.

Authors:  Matcheri S Keshavan; Yoshio Kaneko
Journal:  World Psychiatry       Date:  2013-02       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.